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Oil Dispersants and Human Health Effects
James P. Fabisiak, Ph.D.
Bernard Goldstein, M.D.
Department of Environmental & Occupational Health
Center for Healthy Environments & Communities (CHEC)
University of Pittsburgh Graduate School of Public Health
Introduction & Background
The explosion and subsequent blowout of the Deepwater Horizon (DWH) offshore drilling rig on
April 20, 2010, led to the largest accidental offshore oil spill since the advent of the petroleum
industry, dwarfed only by the deliberate release of crude oil by Iraqi forces during the Persian
Gulf War. Over the time until the well was capped on July 15, approximately 200 million
gallons of oil spilled into the Gulf of Mexico from the ocean floor beneath the well site located
approximately 50 miles off the coast of Louisiana. For perspective, this amount is nearly 20
times the amount of oil discharged during the Exxon Valdez incident in Alaska. As a result,
massive mitigation efforts took place during and after the flow of oil which entailed mechanical
recovery, controlled burning, and chemical dispersion. As a result unprecedented application of
oil dispersant agents was employed by BP during this time until their use was curtailed by the
EPA on May 26, 2010. Overall, about 17 - 20% of the crude oil was mechanically recovered
and 6 – 8% burned. For the oil remaining in the environment, about 40% (of original input) was
evaporated, dissolved, or dispersed into small droplets by natural processes. Initially, it was
estimated that only 16.5 million gallons of oil (<10% of total spill) were dispersed into the
environment by chemical means, however this approximation was revised upward by 2-fold.
The unaccounted for percentages of original oil presumably remain on the surface or washed on
shore1.
Oil dispersants are chemical mixtures of surface active agents and solvents designed to combine
with large floating masses of oil and facilitate the dispersion of the oil into small microscopic
droplets that then disperse throughout the water column. The micro-sized oil droplets can then
be carried and diluted into the open ocean rather than wash ashore or adhere to wildlife and
marine equipment. While it is assumed that dispersed oil is more readily degraded by microbial
or physical processes, it can also increase the bioavailability of oil constituents and alter routes
and extent of exposure to various toxic chemicals contained in the oil.
Potentially hazardous constituents of concern in dispersants
Currently there are 12 oil dispersant products approved for use by the US EPA and the chemical
composition of most remains proprietary information. Even when the specific chemical
ingredients are made available, the precise proportion of each entity contained in the product
mixture is either not declared, or else specified only over a rather broad range. Table 1 lists these
products along with their ingredients, if available. It is estimated that over 1.8 million gallons of
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COREXIT 9500 and COREXIT 9527 were applied during these efforts, including the novel
deepwater use of about 800,000 gallons injected below the ocean surface in an attempt to
intercept the gushing oil plume located near the source. Early on in the mitigation effort
COREXIT 9527 was used, however, due to limited on-hand availability, COREXIT 9500 was
substituted as the primary product employed. It remains unclear as to how much of each
particular product was used. As the crisis unfolded public perception and opinion became
concerned with the additional threat to the environment and human health posed by application
of hazardous chemicals in dispersants, as well as the toxic components within the oil itself. The
initial withholding of information concerning the chemical composition of the dispersant
contributed greatly to public concern. Identification of specific ingredients allows some
estimation of their potential toxicity, however, it must be emphasized that human exposures to
oil dispersants represent exposures to complex mixtures of the specific ingredients, as well as, in
combination with oil components. Much less information is available regarding how such
combinations of chemical agents might interact.
Broadly, the potentially hazardous effects represented by the oil dispersants can be divided into
two classes. The first are direct toxic effects of the agents contained in the oil dispersant
product. The second is the potential to modify the environmental deposition and/or
bioavailability of toxic principals within the oil itself. This will be discussed in more detail
below. It is difficult to comment on the specific ingredients contained in the products whose
formulation remains a trade secret. We can, however, provide some insight regarding those
whose formulation is known and, in fact, represent those used almost exclusively in the DWH
incident (COREXIT 9500 and 9527). Therefore, we will restrict our discussion primarily to the
following specific chemicals: Dioctyl sodium sulfosuccinate, 2-butoxyethanol, 1-(2-butoxy-1methylethoxy)-2-propanol, and ethoxylated alcohols. Some of the products also contain various
petroleum-derived products. For example, COREXIT 9500 contains a large amount (10 – 30%)
of hydrotreated light petroleum distillate (CAS #64742-47-8), which contains primarily C9 – C12
saturated paraffinic hydrocarbons with less than 1% aromatic hydrocarbon content. Other
distillate fractions employed as solvents may contain varying amounts of additional aliphatic and
aromatic compounds depending on the distillation process. Numerous toxic effects, including
malignancy, on a variety of target organs including central nervous system, lung, skin, liver, and
bone marrow have been established for several of these components and thus they can contribute
to the overall burden of toxic chemicals released during the DWH incident. Since, however,
these chemicals are also present as components of the crude oil itself, we will limit our further
discussion of toxicologic profiles to those agents specific to the dispersants. Sorbitan octanoate
and its polyoxyethylene derivatives, used extensively as food and cosmetic additives, appear to
be relatively non-toxic, aside from occasional reports of hypersensitivity and will not be
discussed further. They may, however, like other surface active agents, contribute to the ability
of dispersants to modulate exposure to oil components. We present here primarily toxicity data
pertinent to single agents, however, it is important to remember that dispersants are complex
mixtures and, thus, the potential for interactions between individual components is high, yet
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difficult to predict.
Dioctyl sodium sulfosuccinate (DSS) (IUPAC: Sodium 1,4-bis(2-ethylhexoxy)-1,4dioxobutane-2-sulfonate) (CAS #577-11-7) is an anionic surfactant and a common ingredient in
several household products. It is best known as the active ingredient contained in many overthe-counter stool softeners and laxatives (ex. Colace™, Ducosoft™, Ducolax™, Ex-lax™ stool
softener among others). As such it is usually taken orally but can also be given by rectal enema.
The recommended daily dose is between 50 and 200 mg (0.7 – 2.9 mg/kg b.w.) with up to 500
mg/day sometimes used. It also has been used as a pesticide on grapes, oranges, feed corn,
almonds, nectarines2. Systemic absorption after oral administration has been documented in
humans3, but its extent has not been well studied. Absorption in the rat appears extensive with
subsequent metabolism and combined urinary (60%) and biliary (40%) excretion. Some concern
has been given regarding the potential to produce 2-ethyl-hexanol as a metabolite but so far this
pathway appears to be nominal3b, 4.
Most of the untoward effects seem to be mechanism related and usually manifest as
gastrointestinal symptoms including bloating, diarrhea, cramping, GI upset/pain. Prolonged use
in the face of such symptoms can conceivably produce dehydration and electrolyte imbalances.
The acute LD50 in mice ranges from 1.5 g/kg5 to 4.8 g/kg6. The LD50 in guinea pig was only
0.65 g/kg and horses appeared similarly susceptible to the adverse effects of the drug7. Cause of
death was hypovolemic shock and circulatory collapse attendant with loss of fluid into the
intestinal lumens, thus is essentially related to the mechanism of its therapeutic action. Several
prolonged exposure studies similarly noted GI changes, however, consistently failed to show any
changes in other systemic organ systems8. No evidence appears that DSS is carcinogenic.
Chronic feeding of DSS (1% of diet) failed to show any promotional activity of tumors induced
in response to 1,2-dimethylhydrazine (20 mg/kg/week, s.c) and, in fact, reduced the number of
tumors seen at lower doses of initiator (10 mg/kg/week, s.c)9. In a three generation feeding study
in rats 0.5 and 1% DSS in the diet caused a reduction in body weight, however, reproductive
performance remained normal throughout the study and no treatment-related macroscopic
changes were observed10. In a retrospective study where 6,937 women were prescribed drugs
during the first trimester of pregnancy, 473 received DSS with only a single birth of a child with
an unspecified congenital disorder11. Allergic hypersensitivity reactions have been reported12 but
the incidence of anaphylaxis appears low. As reported by eHealthMe.com, a website that tracks
post-marketing adverse event reporting to the FDA, only one case of anaphylaxis was reported
out of the 411 people who reported side effects to Colace™13. Prescribing information for
products containing DSS warn against concomitant use of mineral oil since therapeutic doses of
DSS may enhance systemic absorption of mineral oil. This effect serves as a harbinger of the
possible toxic interactions between oil dispersants and oil components.
2-Butoxyethanol (2-BE): 2-BE (CAS #111-76-2) (ethylene glycol monobutyl ether, monobutyl
glycol ether, Butyl CelluSolve™, Dowanol™ EB) is a high-production volume solvent in the
chemical class of glycol ethers. The structural formula of 2-BE is CH3CH3CH2-O-CH2CH2-OH.
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It is a member of a larger class of ethylene gycol ethers that include 2-methoxyethanol and 2ethoxyethanol, as well as higher series of ethoxylated fatty alcohols. 2-BE is widely used in the
manufacture of various enamels, lacquers, paints and other surface coatings. In addition, it is
also commonly found in a variety of household cleaners and products. Because of its relatively
high vapor pressure it can exist in the atmosphere as a vapor. 2-BE is also easily miscible in
water and most organic solvents. Because of its aqueous miscibility, the propensity to produce a
vapor phase is reduced upon addition to water. As such, the primary routes of exposure thought
to be of concern are respiratory and dermal, although accidental/intentional ingestion of some 2BE containing products have been documented. 2-BE can be readily absorbed via all three major
routes of exposure. In fact, percutaneous absorption through the skin is thought to be a
significant route of exposure for vaporous 2-BE within the atmosphere14. In addition, it appears
that 2-BE is much more efficiently absorbed from an aqueous solution applied to the skin
compared to an equivalent dose applied as a neat solution15. While most of the dispersant
products are recommended for use as undiluted solutions for aerial application, others like
COREXIT EC7664A, a surface washing agent, are applied as a 1- 3% diluted solution16. Boat
spraying of COREXIT 9500 and 9527 products requires specialized low-pressure low-volume
pumps, which if unavailable, may necessitate use of diluted product down to 5 – 10%.17
The metabolism of 2-BE proceeds mostly through typical alcohol and aldehyde dehydrogenase
pathways with formation of 2-butoxyacetaldehyde and 2-butoxyacetic acid (2-BAA), the
principal metabolite18. This raises the possibility of competitive inhibition of metabolism by
other primary alcohols like ethanol and altered kinetics during consumption of alcohol.
Administration of ethanol to rats significantly increased blood levels of various ethylene glycol
ethers after their inhalation19. At higher concentrations this pathway is likely saturated and
alternate pathways of O-dealkylation and glucuronidation become more quantitatively
important18b. An amino acid conjugate, n-butoxyacetylglutamine, has been identified in humans
but not experimental animals20.
The principal health effect of 2-BE observed in humans is central nervous system toxicity with
additional kidney and liver injury at high doses. 2-BE can produce an acute CNS syndrome
typical of exposure to other organic solvents consisting of dizziness, nausea, vomiting, loss of
coordination, ataxia, confusion, depression, loss of consciousness. Severity is related to the
dose. 2-BE is also an irritant to mucosal surfaces and skin, therefore ocular, oro-pharyngeal,
nasal, respiratory, and dermal symptoms are also observed. 2-BE does not appear to be a skin
sensitizer in humans21.
Acute LC50s or LD50s have been established in several species and are summarized in Table 222.
Much of the concern regarding 2-BE stems from its established ability to produce profound
intravascular hemolytic anemia in experimental animals. This effect is characterized by a
decreased number of circulating red blood cells (RBCs) and elevations in free hemogoblin. Free
hemoglobin is believed to be responsible for the observed tissue damage especially in the
kidneys and liver. Inhalation of 2-BE by female rats (62 ppm, 299 mg/m3) for 4 hrs increased
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osmotic fragility of erythrocytes23. This effect has been documented repeatedly in multiple
species including dog, rabbit, and with both acute and longer term-exposure23-24. Older rats
appear more sensitive than younger animals25, as well as female compared to male rats26. These
observations likely reflect the greater accumulation of the metabolite 2-BAA in both sensitive
groups (see below)25, 27. In vitro studies using isolated erythrocytes have provided important
insights into 2-BE induced hemolysis. The 2-BAA metabolite of 2-BE appears to be the primary
offending species for these effects since in vitro incubation of isolated red blood cells with BAA
produced hemolysis at between 20 – 40-fold lower concentrations than the parent compound24b,
28
. Importantly, the same studies observed marked species differences in sensitivity to the
hemolytic effects. Human RBCs were markedly more resistant to these effects than rats24b, 28
requiring nearly 10 times more BAA to produce hemolysis. Other sensitive species include
mice, hamsters, rabbits, and baboons, while resistant species include pigs, dogs, cats, and guinea
pigs29. These species differences in part reflect intrinsic differences in the red blood cells
themselves, presumably at the level of membrane composition. 2-BE-induced frank hemolysis is
rarely reported in humans, even during severe poisonings following suicide attempts (ingestion
of 25 – 60 gm)30. Occupationally relevant exposures (100 ppm) could produce headache and
vomiting but no signs of hemolysis, although higher exposures have been shown to alter osmotic
fragility when tested in vitro23, 31. During a controlled human exposure study, vomiting and
headache were observed after breathing 100 ppm (483 mg/mm3) for 8 hrs. No clinical signs of
hemolysis were observed at any level although exposure to 195 ppm (942 mg/m3) did increase
osmotic fragility of RBCs when assessed in vitro23. After in vitro incubation of human RBCs
with 2 mM BAA, a concentration which causes complete lysis rat RBCs, Udden observed no
changes in morphology or deformability even in cells derived from patients with hereditary
spherocytosis, a disorder characterized by red cells with high osmotic fragility, and sickle cell
disease32.
Reproductive toxicity (both male and female) has been observed with the related glycol ethers,
2-methoxyethanol and 2-ethoxyethanol, however, 2-BE appears relatively devoid of reproductive
and developmental effects. No testicular effects were observed in rodents exposed to 2-BE by
inhalation of 800 ppm for 3 hrs33 or oral administration of up to 2000 mg/kg/day, 5 days/week,
for 5 weeks34. Developmental studies exposing pregnant dams to 2-BE by a variety of routes
failed to show any fetotoxic or teratogenic effects except at doses that produced significant
maternal toxicity35. While in vitro tests for mutagenic and genotoxic effects have yielded
equivocal results36 in vivo tests have been largely negative. 2-BE was negative in the bone
marrow micronucleus test after i.p. administration in rats and mice36c, 37. Using [32P]-postlabelling assay, no DNA adducts were observed in multiple organs of orally dosed-rats38. Keith
et al. showed no effects on DNA methylation in multiple organs and tumor formation in FVB/N
transgenic mice38. 2-BE has been associated with formation of hemiangiosarcomas in liver and
other organs of mice39, however, these tumors are now thought to arise secondarily through the
heme-dependent generation of reactive oxygen species and hypoxia-dependent proliferative
signaling in endothelial cells, which arise during the hemolytic destruction of RBCs40. Since
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these tumors appear only in the context of profound hemolytic effects, they are thought not to be
of significance in human exposures.
1-(2-butoxy-1-methylethoxy)-2-propanol (CAS # 29911-28-2), more commonly referred to as
dipropylene glycol n-butyl ether (DPnB), is a component of both COREXIT 9500 and 9527.
Synonyms for this compound include 2-(butoxypropoxy)-2-propanol, dipropylene glycol
monobutyl ether, ARCOSOLV™ DPNB, or DOWANOL™ DPNB. DPnB is also a glycol ether,
except it is classified as a P-series glycol ether (synthesized from propylene oxide) unlike 2-BE
discussed above whose synthesis is based on ethylene oxide (E-series) as the starting material.
In general, the P-series glycol ethers are frequently considered safer alternative to E-series
compounds as they lack the hemolytic toxicity and appear to have less potential to disrupt
reproductive function and fetal development41. Little of the descriptive toxicology, however,
appears in the peer-reviewed literature but instead relies upon industry-sponsored unpublished
studies. DPnB (Table 2), as well as other propylene glycol ethers, have very low acute toxicity
with LD50s greater than 1,800 mg/kg in oral studies, 2,000 mg/kg for dermal exposures, and
>250 ppm for inhalation exposures42. In many cases, the actual LD50 were not obtained within
the dose range employed. When signs of toxicity were observed, they usually included
generalized CNS and respiratory depression common with exposure to other solvents. DPnB
was classified as ”slight irritating” to skin and eyes43, but no evidence of sensitization was
observed44. An intriguing peer-reviewed study, however, has recently appeared that begs further
consideration. Choi et al. 45 conducted a case-control study correlating household levels of
different classes of indoor air volatile organic compounds (VOCs) with allergic disease and IgE
sensitization. Of the 8 different classes of VOCs including aromatic hydrocarbons, aldehydes,
organic acids, and others, only the propylene glycol and glycol ethers were associated with
increased risk of multiple allergic symptoms and atopy. Therefore, the association of glycol
ethers to asthma and other allergic diseases deserves further attention although the actual
offending chemical(s) have not been identified.
Longer term exposure studies also revealed relatively benign effects. Two-week inhalation
studies in rats exposed to DPnB demonstrated a threshold for toxicity somewhere between 320
mg/m3 (40 ppm) and 810 mg/m3 (104 ppm)46.
Toxicity manifested primarily as
histopathological lesions in the liver and nasal mucosa. In this regard, DPnB appears slightly
more toxic that other propylene glycol ethers such as propylene glycol n-butyl ether47. 47cDermal
exposure to rats for up to 13 weeks produced some localized skin irritation at all doses but little
in the way of systemic toxicity except small decreases in body weight and elevated neutrophil
counts with a NOAEL of 0.1 ml/kg-day (91 mg/kg-day) and LOAEL of 0.3 ml/kg-day (273
mg/kg-day)48. Prolonged oral exposure (13 weeks) produced slight elevations in liver and
kidney weights without histopathology and mild changes in clinical chemistries only at the
highest dose tested (1,000 mg/kg/day)49. Importantly, these studies, as well as one specifically
designed to test hematological effects50, demonstrated that propylene glycol ethers do not share
the hemolytic effects manifest by their E-series relative, 2-BE, as discussed above. Functional

	
  

7	
  

reproductive studies with DPnB have not been carried out but no changes in the reproductive
organs were observed at necropsy in any of the repeated dosing studies listed above and
reproductive endpoints after exposure to the structurally-related propylene glycol monomethyl
ether51 were negative. Developmental studies during dermal exposure of rats established a
LOAEL of > 910 mg/kg/day (the highest doses applied in each study), respectively, for maternal
toxicity, embryo-/fetal toxicity, or developmental aberrations52. In most studies DPnB is not
mutagenic by in vitro or in vivo assays53, however, three tests all from a single laboratory
showed chromosomal aberrations in CHO cells54. National Toxicology Program testing for
carcinogenic effect of the related agent, propylene glycol monobutyl ether, observed an increase
in hepatic tumors in male and female mice, but not rats exposed to 1,200 ppm by whole-body
inhalation (the highest dose tested) for 2 years55. Male mice showed exposure-related increases
in non-neoplastic lesion in the kidney with equivocal increases in renal neoplasia. DPnB has not
been similarly tested for tumorigenic potential in long-term studies. Therefore, with the paucity
of in vivo data, as well as, equivocal in vitro results, formation of hepatic lesions with
preneoplastic potential, and tumorigenic effects of structurally-related compounds, labeling
DPnB as non-carcinogenic should be taken with some caution.
One likely explanation for the dramatic differences between the structurally similar 2-BE and
PGBE relates to differences in metabolism. It is believed that the major offending species for
hematologic and reproductive toxicity seen with the E-series glycol ethers is the corresponding
acid produced during in vivo metabolism by alcohol and aldehyde dehydrogenases (2-butoxy
acetic acid in the case of 2-BE). The major species (>95%) contained in commercial
preparations of PGBE, however, is the alpha isomer which represents a secondary alcohol, thus
is not a substrate for alcohol dehydrogenase and incapable of forming an alkoxypropionic acid.
Instead, metabolism of PGBE proceeds largely by typical mixed function oxidase-dependent Odealkylation yielding t-butanol and propylene glycol. Propylene glycol is readily converted to
lactate and pyruvate for consumption in the Krebs cycle. t-butanol, as well as some of the parent
compound, is excreted as a glucuronide conjugate56.
Ethoxylated alcohols deserve a brief mention here in that they are chemically related to simpler
glycol ethers. They are usually composed of a long chain fatty alcohol (C8 – C15) linked to a
polyethelyene glycol chain also of varying length (1-20). Modulation of the length of the carbon
chains as well as the number of ethoxy units can be used to determine specific properties of these
non-ionic surfactants. One of the approved oil dispersant products, DISPERSIT SPC 1000
contains ethoxylated alcohol specified as a mixture of C12 – C14 fatty alcohol without noting the
relative degree of ethoxylation. While these chemicals have undergone considerable scrutiny in
terms of their potential environmental toxicity, there is very little information regarding their
effects on humans or other mammals. Various MSDS sheets for these compounds note them to
be significant irritants upon ocular or dermal exposure, but no long term systemic toxicities are
reported at typical usage exposures. One possible issue to consider is the fact that atmospheric
(and perhaps microbial) oxidation of these chemicals can give rise to reactive aldehydes with
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potential to produce contact sensitization and subsequent allergic reactions upon re-exposure57.
Secondary effects by altering oil component exposure
Crude oil represents a complex mixture containing a vast array of aliphatic and aromatic
hydrocarbons, heavy metals, and other substances. The total petroleum hydrocarbon (TPH)
fraction represents the greatest concern to human health. Depending on the carbon chain length
or number of aromatic rings each compound has its unique profile of volatility, solubility, and
physical-chemical properties that ultimately determine its toxicokinetics and toxicodynamics.
The low-molecular weight BTEX fraction (benzene, toluene, ethylbenzene, xylene) is of concern
because they can diffuse into aqueous media as well as readily volatalize from a surface film of
oil. The carcinogenic effects of benzene are well-known as a leading cause in acute
myelogenous leukemia58. Larger molecular weight species (naphthalene, benzopyrene) may
remain more associated with the crude oil mass, but still possess toxic potential. An actual
description of the specific adverse health effects of TPH is beyond the scope of this discussion,
but the interested reader is referred to ATSDR profile for Total Petroleum Hydrocarbons59.
Perhaps, the biggest question regarding the action of oil dispersants is how they might modulate
the fate and transport of various oil constituents within the environment. By their nature they are
designed to break up the oil mass into tiny micro-sized droplets that remain suspended within the
water column rather than form a “slick” on the water surface. Wave tank experiments indicate
the size of chemically-dispersed oil droplets to be in the 10 – 50 µm range with some even
smaller, although the size of oil droplets formed over time after application of dispersants in the
natural setting of an accidental spill is not well studied60. This might reduce the evaporation of
BTEX components, for example, reducing atmospheric concentrations and thus inhalational
exposure. The concentration of these species, as well as heavier compounds, however, are now
also increased within the water, and may promote exposure via dermal contact (swimming,
water-on-skin exposure during clean-up operations, aerosol generation during wave action), as
well as increasing the possibility that such chemicals might sequester in various marine biota
because of their potential to bioaccumulate. Such physical dispersion of the oil mass into an
emulsion of microscopically-sized particles dramatically increases the surface area of the overall
oil-water interface where diffusion and absorptive processes proceed. The absence of a distinct
odor of volatile oil components, as well as visual evidence of an oil slick could also impart a
false sense of security when it comes to use of personal protection equipment such as
respirators/filters, gloves, and other body coverings.
Of note is the hypothesis that the presence of oil dispersants can also directly affect how various
chemicals enter the body. Again the increase in surface area whereby oil-derived chemicals
might contact the skin and lung lining might facilitate absorption by the dermal and inhalation
routes. We mentioned above that water mixtures of glycol ethers showed enhanced dermal
absorption above that seen when glycol ethers are exposed neatly to the skin15, however, the
dermal absorption of dispersed TPH components has not been compared to those in undispersed
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oil. DSS, under the trade name Aerosol-OT, has received recent attention as a means to enhance
oral absorption of various pharmaceuticals and is the subject of patents for improved drugdelivery systems61. DSS enhanced the efficacy of tetracycline on various microorganisms,
including some normally resistant to the drug, by enhancing intracellular permeation of the
drug62. Aerosol OT/1-butanol emulsions were also found to markedly enhance penetration of the
antibiotic, clindamycin phosphate, through human epidermis when compared to a 70%
isopropanol vehicle63. The ability of Aerosol OT to similarly enhance diffusion of 5-fluorouracil
through skin was accompanied by modifications in the lipid structure and degree of hydration of
the stratum corneum layer of the skin64. Thus, it is entirely possible that DSS and various other
surface active agents in dispersant products can enhance absorption of specific TPH components
and thus potentiate any adverse effects resulting from such exposures. Because of its volatility,
most benzene applied to skin is expected to evaporate before substantial systemic absorption. If,
however, benzene is sequestered into an emulsified aqueous suspension by the action of
dispersants its potential for evaporation and, therefore, dermal absorption might be modified.
While direct administration of DSS (1%) into the lungs of dogs produced some pulmonary
edema65, DSS aerosols (5%) accelerated lung clearance of the tracer, 99Tc-diethylenetriamine
pentaacetate (99Tc-DPTA) without affecting gas exchange or lung mechanics66. In fact, DSS has
been considered as a means to enhance delivery of pharmaceutical agents via enhancing alveolar
absorption67. In rabbits, DSS successfully enhanced the absorption and biological action of
insulin delivered by aerosol inhalation68.
Probable exposure scenarios and possible at-risk groups
It is expected that those individuals directly involved with the clean-up operations and direct
handling/application of the dispersants would have received the highest exposure and, therefore,
are the most at risk for adverse effects. In these cases their most likely route of exposure was via
inhalation or dermal absorption. The National Institute for Occupational Safety and Health
conducted a limited series of health hazard evaluations for several groups of responders
employed during the spill clean-up69. The most commonly reported symptoms were headache,
upper respiratory symptoms, and symptoms related to heat stress. While workers who reported
exposures to oil and dispersants reported higher prevalence of all types of symptoms, no
assignment of specific causative agents could be made. Health symptom surveys taken aboard
two vessels actively engaged in releasing dispersants were similar in scope and magnitude to
those obtained from other workers who had not worked on boats and had no exposures to oil or
dispersants. Personal breathing zone and area air sampling was used to evaluate exposure to a
variety of chemicals, including propylene glycol, a COREXIT component, and measured levels
that that were consistently below the acceptable occupational exposure limit (OEL). Moreover,
NIOSH investigators consistently noted that workers generally complied with wearing the
necessary personal protection equipment required for the task at hand.
Local populations residing on the shores are likely at minimal risk for toxicity based on dilution
of the chemicals in surrounding water and air. Aerial application of dispersants occurred only at
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distances greater than 3 miles from shore and serves to severely limit respiratory and dermal
exposure on the shoreline. Some concern has been raised about potential contamination of
seafood with chemical dispersants. The environmental half-life of these compounds is short and
there is little evidence that any of the chemicals discussed above appreciably bioconcentrate or
accumulate within the food chain. Trace levels of DSS measured in seafood samples tested after
the opening of previously closed waters were considered insignificant to human health by the
FDA.
As always the primary at-risk groups based on the limited knowledge we have are the very
young, the elderly, and those with preexisting conditions especially chronic lung disease. The
clean-up worker investigation conducted by NIOH noted a disproportionate number of smokers
among the clean-up workers69. Pregnant and nursing women should also be advised to minimize
potential exposure simply as a matter of common sense. It is possible that the capacity for
metabolism can also determine sensitivity. For example, individuals who possess high levels
alcohol dehydrogenase activity (those of Asian or Amerindian descent, for example) might
actually be sensitive to some of the effects of 2-BE compared to others with less functional
capacity to generate the more toxic metabolite, 2-BAA. Similarly, genotypic/phenotypic
variability in the cytochrome P450(s) responsible for O-dealkylation of propylene glycol ethers
could contribute to alterations in the physiological disposition of P-series glycol ethers. No
specific studies, however, have addressed these issues.
Perceived Safe Levels
No environmental or occupational regulatory/occupational standards for air or water exist for
DSS. Because of its use as an OTC medicine and possible application of as food additive, the
Acceptable Daily Intake as set by the WHO Joint Expert Committee on Food Additives is 6
mg/person/day and that set by the U.S. FDA is 30 mg/person/day. As a stool softener the
recommended adult doses are in the range of 100 – 500 mg/day and appear to be well tolerated
over extended periods of time. Because of their high vapor pressures, regulatory guidelines have
been set for the glycol ethers. The following air standards for 2-BE have been set: TLV TWA
(Threshold Limit Value, AIGIH) = 25 ppm, PEL (Permissible Exposure Limit, OSHA) = 50
ppm, and IDLH (Immediately Dangerous to Life or Health, NIOSH) = 700 ppm. No limits have
been set specifically for DPnB, but those corresponding to dipropylene glycol monomethyl ether
are TLV =100 ppm and STEL (short-term exposure limit, ACGIH) = 150 ppm.
Potential relevant biomarkers and future studies
It will be a challenge to ascertain whether the application of oil dispersants into the Gulf of
Mexico will have any perceptible effects on human health. The NIH-sponsored Gulf Long term
Follow-up (GuLF) Study, led by NIEHS, is set to begin to study clean-up workers and volunteers
to understand the scope and diversity of adverse health effects amongst those individuals most
highly exposed to the toxic agents in question. One of its major challenges, however, will be to
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accurately characterize and quantify exposure to specific oil and dispersant chemicals alone, as
well as in mixtures. Clearly, one of the prime issues will be to determine specific populations
who were exposed to these agents and quantify the extent of their exposure in terms of time and
amount. Detailed clean-up worker histories might allow grouping of workers based on their
proximity in time and space to actual application of dispersants and comparing their ultimate
health outcomes to oil clean-up workers with similar tasks in regions where dispersants were not
applied. Clearly, a more accurate way to document exposure (an internal dose) would be to
measure parent compounds or their metabolites in biological samples (blood, urine, other).
However, the pathways of metabolism of DSS are not well described. Measurement of urinary
2-BAA has proven useful in monitoring employees potentially exposed to 2-BE in other
settings70. It is important to remember, however, that these approaches are most useful only in
the early stages following exposure since the compounds are presumably cleared fairly rapidly in
the absence of a continuous exposure source. Moreover, there clearly are other sources of
exposure for these agents such as laxative use and various household cleaning products
containing glycol ethers. Therefore, for local residents not directly involved in clean-up
activities, the background levels of exposure to many of these agents from other sources may
approximate, or even exceed, those specifically from dispersant use. While biomarkers of effect
would be useful, there are relatively few, if any, specific for these compounds. Measurement of
RBC osmotic fragility could be used to monitor the hemolytic signature effect of E-series glycol
ethers, but recall that humans are amongst the least sensitive species for this effect. Various
measures of DNA damage and adduct formation in peripheral blood cells has provided some
utility in measuring potential genotoxic effects after other oil spills.
The most fruitful future studies might be in regard to studying the interactions between oil
dispersants and specific TPH components within the oil itself. Some chemicals in TPH might be
more persistent than the dispersant chemicals so measurement of body burden with and without
dispersant exposure might prove informative. Animal and in vitro studies that address
availability and toxicity of TPH components in the presence and absence of dispersants should
be carried out. For example, does simultaneous inclusion of dispersants in TPH component
feeding studies alter the genotoxic and tumorgenic effects? Direct in vitro studies can easily be
performed to determine if DSS or other oil dispersant components can increase permeation of oil
components across skin. Human skin models employing cadaver-derived or tissue-engineered
skin are routinely used to assess xenobiotic transport across this barrier in specifically-designed
diffusion barrier chambers.
As pointed out earlier, the dispersant products themselves represent complex mixtures whose
toxicity may not be adequately predicted by knowledge of the single ingredients alone. Few
studies have directly tested the dispersant products for toxicity. Recently, the irritant and
sensitizing properties of COREXIT 9500A and DSS were compared in a dermal application
model in rats71. COREXIT was found to be about 10-fold more potent than would be expected
based in its content of DSS alone. Acute 5 hr exposure of rats (27 mg/m3) of COREXIT aerosols
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was found to induce a small change in lung compliance without inflammation72 and changes in
peripheral vascular reactivity73. These effects, however, were transient and extrapolation of the
exposures conditions to those encountered in the real world is problematic.
Summary
The massive deployment of oil dispersants in the Gulf of Mexico in response to the DWH oil
spill has raised concerns regarding their potential adverse effects to the environment and human
health. The specific ingredients contained in many oil dispersant products remain proprietary
information, however, those contained in COREXIT 9500 and COREXIT 9527, the products
used almost exclusively in the Gulf, were available for review. Exposure of the general populace
of Gulf shore to the major ingredients dioctyl sodium sulfosuccinate, 2-butoxyethanol, propylene
glycol butyl ether, and other ethoxylated alcohols should be considerably below the range
expected to produce adverse effects based on a review of their toxicological profiles. Of note,
however, is the severe paucity of both human and laboratory data regarding the potential effects
of chemical mixtures as represented by oil dispersant products. Those individuals involved in
clean-up operations that directly handled oil dispersants or worked in the immediate area of
application probably encountered greater amounts of dispersants and might a greater risk of
adverse effects, but, in general these should be mild and self-limiting. Importantly, for several of
the major toxicities described in experimental animals, humans appear to comparatively
resistant. Perhaps a greater question pertains to the ability of dispersants to alter the
toxicological properties of the chemicals contained in the oil itself. By their nature they are
designed to alter the fate and transport of crude petroleum and its constituents and, therefore, can
change the route and extent of human exposures. The physico-chemical properties of petroleum
hydrocarbons contained in micro- -sized oil droplets desperately needs to evaluated and
compared to petroleum hydrocarbons alone, in simple aqueous solution, and in air. Moreover,
some the oil dispersant products themselves have potential to directly modify biological barriers
and, thus, alter permeation of oil-derived chemicals at various routes of exposure.
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Table 1. Approved Oil Dispersant Products and Their Ingredients

Product

Ingredients

BIODISPERS
(Petrotech America)

Proprietary

JD-109
(GlobeMark Resources Ltd.)

Proprietary

JD-2000
(GlobeMark Resources Ltd.)

Proprietary

NOKOMIS 3-AA
(Mar-Len Supply, Inc.)

Proprietary

NOKOMIS 3-F4
(Mar-Len Supply, Inc.)

Proprietary

COREXIT 9500
(Nalco Energy Services)

Sorbitan, mono-(9Z)-9-octadecenoate
Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2- ethanediyl) derivs.
Sorbitan, tri-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.
Butanedioic acid, sulfo-, 1,4-bis(2-ethylhexyl) ester, sodium salt
(Dioctyl sodium sulfosuccinate) (10 – 30%)
1-(2-butoxy-1-methylethoxy)-2-propanol (1 – 5%)
Distillates (petroleum), hydrotreated light (10 – 30%)

COREXIT 9527
(Nalco Energy Services)

Sorbitan, mono-(9Z)-9-octadecenoate
Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.
Sorbitan, tri-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.
Butanedioic acid, sulfo-, 1,4-bis(2-ethylhexyl) ester, sodium salt
(Dioctyl sodium sulfosuccinate) (10 – 30%)
1-(2-butoxy-1-methylethoxy)-2-propanol (1 – 5%)
Distillates (petroleum), hydrotreated light
2-Butoxy-ethanol (30 – 60%)

MARE CLEAN 200
(Taiho Industries Co. Ltd.)

Poly(oxy - 1,2 - ethanediyl), α- hydro - ω - hydroxy - , ether with 1,2,3 propanetriol (9Z) - 9 - octadecenoate
Poly(oxy - 1,2 - ethanediyl), α- (9Z)- 1 - oxo - 9 - octadecen - 1 - yl - ωhydroxyPoly(oxy - 1,2 - ethanediyl), .α- (9Z) - 1 - oxo - 9 - octadecen - 1 - yl -ω(9Z) - 1 - oxo - 9 - octadecen - 1 - yl oxy - (Polyethylene Glycol
Dioleate)
Sorbitan, tri-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.
(Polysorbate 85)
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Alkanes, C14-30
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Table 1. Approved Oil Dispersant Products and Their Ingredients (con’t)
DISPERSIT SPC 1000
(U.S. Polychemical Corp.)

Poly(oxy - 1,2 - ethanediyl), α- (9Z)- 1 - oxo - 9 - octadecen - 1 - yl - ωhydroxyl
Ethoxylated Amines, tallow alkyl
N,N-bis(hydroxyethyl)- Amides, coco
Ethoxylated Alcohols, C12-14-secondary,
1(or 2) - (2-methoxymethylethoxy) - propanol

SAF-RON Gold
(Sustainable Environmental
Technologies, Inc.)

Proprietary

NEOS AB3000
(Neos Company, Ltd.)

Proprietary

SEA BRAT 4
(Alabaster Corp.)

Proprietary
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Table 2. Acute Toxicity of 2-Butoxyethanol (2-BE) and Dipropylene Glycol n-t-Butyl Ether (DPnB)
in Various Species and Routes of Exposure
Route of Administration
Inhalation
2-BE

DPnB

Species Tested

LC50 or LD50

Male rats (4 hr)
Female rats (4 hr)
Mice (7 hrs)
Guinea Pigs (1 hr)

486 ppm (2347 mg/m3)
450 ppm (2174 mg/m3)
700 ppm (3381 mg/m3)
650 ppm (3140 mg/m3)

Rats (4 hr)

> 42 ppm (> 328 mg/m3)
(no deaths)
> 262 ppm (> 2,040 mg/m3)
(no deaths)

Rats (4 hr)
Oral
2-BE

Rats
Mice
Guinea Pigs
Rabbits

2500 mg/kg b.w.
1400mg/kg b.w.
1200 mg/kg b.w.
320 mg/kg b.w.

DPnB

Rats
Rats
Mice

4000 mg/kg
1850 mg/kg
2160 mg/kg

2-BE

Rabbits
Guinea Pigs

404-502 mg/kg b.w.
2000 mg/kg b.w.

DPnB

Rat

Dermal

(length of exposure)

> 2000 mg/kg (no deaths)

